PMID- 11133185
OWN - NLM
STAT- MEDLINE
DCOM- 20010517
LR  - 20131121
IS  - 0014-4835 (Print)
IS  - 0014-4835 (Linking)
VI  - 72
IP  - 1
DP  - 2001 Jan
TI  - Topically applied betaxolol attenuates ischaemia-induced effects to the rat 
      retina and stimulates BDNF mRNA.
PG  - 79-86
AB  - It has previously been reported that the beta(1)-adrenoceptor antagonist, 
      betaxolol, can protect retinal neurones from ischaemia when applied topically. It 
      has further been shown that betaxolol can reduce influx of both sodium or calcium 
      into neurones through interaction at neurotoxin site 2 of the sodium channel and 
      the L-type calcium channel, respectively. The present study sought to further 
      investigate the neuroprotective mode of action of betaxolol in the rat retina. 
      Rats were treated topically with L-betaxolol for 10, 5 and 1 min before 
      ischaemia, induced by raising the intraocular pressure above systolic blood 
      pressure for 45 min. This was followed by reperfusion of 3 or 5 days where 
      L-betaxolol was applied topically twice daily. Ischaemia plus reperfusion caused 
      both a loss of immunoreactivity for choline acetyl transferase (ChAT) and a 
      marked reduction of the b-wave of the electroretinogram (ERG). Treatment, as 
      described, with topical L-betaxolol, completely blunted the effects upon ChAT 
      immunoreactivity and caused a significant reversal of the ERG changes. 
      Furthermore, other rats treated topically with commercially available racemic 
      betaxolol (Betoptic Solution, 0.5%) for 6 hr had raised levels of mRNA for brain 
      derived neurotrophic factor (BDNF) but not for basic fibroblast growth factor 
      (bFGF) in their retinas. The combined data provide further evidence that 
      betaxolol can blunt the effects of ischaemia to the rat retina when applied 
      topically just before the insult. Furthermore, the finding that retinal levels of 
      BDNF mRNA are raised following topical betaxolol treatment shows that not only 
      can this drug reach the retina but that it can also induce changes in expression 
      of factors which are known, themselves, to provide neuroprotection to retinal 
      neurones.
CI  - Copyright 2001 Academic Press.
FAU - Wood, J P
AU  - Wood JP
AD  - Nuffield Laboratory of Ophthalmology, Walton Street, Oxford, OX2 6AW, UK.
FAU - DeSantis, L
AU  - DeSantis L
FAU - Chao, H M
AU  - Chao HM
FAU - Osborne, N N
AU  - Osborne NN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (RNA, Messenger)
RN  - EC 2.3.1.6 (Choline O-Acetyltransferase)
RN  - O0ZR1R6RZ2 (Betaxolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Animals
MH  - Betaxolol/*therapeutic use
MH  - Choline O-Acetyltransferase/drug effects/metabolism
MH  - Electroretinography
MH  - Ischemia/*drug therapy
MH  - Nerve Growth Factors/*drug effects/genetics
MH  - Ophthalmic Solutions
MH  - RNA, Messenger/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Retina/*drug effects
MH  - Retinal Vessels/drug effects
EDAT- 2001/01/03 11:00
MHDA- 2001/05/18 10:01
CRDT- 2001/01/03 11:00
PHST- 2001/01/03 11:00 [pubmed]
PHST- 2001/05/18 10:01 [medline]
PHST- 2001/01/03 11:00 [entrez]
AID - S0014-4835(00)90929-1 [pii]
AID - 10.1006/exer.2000.0929 [doi]
PST - ppublish
SO  - Exp Eye Res. 2001 Jan;72(1):79-86. doi: 10.1006/exer.2000.0929.